OSLO, NORWAY: PCI Biotech, a Norwegian cancer focused biopharmaceutical company and MDimune Inc., a private South Korean biotech company developing innovative drug delivery technologies for modifying cellular and disease processes in many areas of human disease, announced a preclinical research collaboration that would offer several opportunities for future development. Commenting on the announcement, Per Walday,…